CTSO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
9.6M
+8.7%
8.9M
-4.0%
9.2M
-2.6%
9.5M
-1.4%
9.6M
Cost of Revenue
2.6M
-5.5%
2.7M
+12.5%
2.4M
-13.8%
2.8M
+0.6%
2.8M
Gross Profit
7.0M
+15.0%
6.1M
-9.9%
6.8M
+2.1%
6.7M
-2.2%
6.8M
Operating Expenses
9.7M
+5.6%
9.2M
-18.0%
11.2M
+17.4%
9.5M
-8.6%
10.4M
R&D
1.5M
+41.8%
1.0M
-17.5%
1.2M
+35.4%
918.0K
-27.3%
1.3M
SG&A
8.0M
-2.3%
8.1M
-13.6%
9.4M
+9.6%
8.6M
-6.1%
9.2M
Operating Income
-2638000
+13.3%
-3044000
+30.6%
-4385000
-53.2%
-2862000
+20.8%
-3615000
EBITDA
-2019000
+25.1%
-2694000
+23.4%
-3516000
-40.8%
-2498000
+22.2%
-3211000
Net Income
-4417000
+13.9%
-5129000
+6.7%
-5497000
-73.4%
-3170000
-262.8%
1.9M
EPS (Basic)
$-0.07
+12.5%
$-0.08
+11.1%
$-0.09
-80.0%
$-0.05
-266.7%
$0.03
EPS (Diluted)
$-0.07
+12.5%
$-0.08
+11.1%
$-0.09
-80.0%
$-0.05
-266.7%
$0.03
Shares (Diluted)
62.8M
+0.1%
62.7M
+7.7%
58.3M
-7.1%
62.8M
-6.6%
67.2M
Cytosorbents (CTSO) โ€” Financials